Did you know that you can order an eco-conscious burger in Houston? Photo courtesy of Hopdoddy

Hearty Austin-based chain Hopdoddy Burger Bar has unveiled a new lineup of regenerative burgers that are supposed to be better for the planet and the consumer.

The term "regenerative burger" could cause a few head-scratches: Some may think of lab-grown or 3D-printed meat, while others think of plant-based alternatives but it’s neither. It is grass-fed meat, sourced a bit differently. "Regenerative farming" is a term used to describe farming and grazing practices that claim to restore and rebuild degraded soil, resulting in better-quality air and water.

Hopdoddy’s vice president of culinary Matt Schweitzer explained that it all began with with a sense of obligation to do better as a brand for the consumers and the ecosystem.

“We felt like we could really take a stand and look to move our entire supply chain in a regenerative fashion, so we could really be proud of the work we’ve done and we could hopefully leave the animals, the farmers, the ranchers, the native grasslands, and our planet a better place than before we started,” says Schweitzer.

The new menu items include the "Roosevelt Burger" with grass-fed regenerative bison; the "Nashville Hot Sandwich" with regenerative raised chicken; the "Regenerative Royale," which is a play on a classic double quarter-pounder with cheese; the "Mother Nature" with grass-fed regenerative beef; and the "Buffalo Bill" also uses regenerative bison, but appears not to be grass-fed.

The five burgers are available at all Hopdoddy locations nationwide. The beef and bison are sourced from Texas-based regenerative company Force of Nature, while the chicken is from Cooks Venture.

With this launch, Hopdoddy removes all plant-based meat substitutes from its menu, significantly reducing the options for vegans and vegetarians. The company felt the ingredients and ethos of the alternative meats — describing some such as Beyond Meats as "falsely advertised" regarding nutrition in a press release — no longer aligned with its values and mission. However, the house-made veggie patty remains on the signature "El Bandito" burger.

Schweitzer says the regenerative burgers have received positive feedback, as people are excited to know where their food comes from, how it gets to their table, and what type of impact it causes. Regarding the future of regenerative meat, he says there is no doubt it could become mainstream soon.

“I think the flavor profile, the eating experience, the story, the mission, the purpose, really speaks for itself," says Schweitzer. "So, I really think it’s a matter of time until 'regenerative' is talked about in the same way that 'organic,' or 'sustainable,' or those type of buzzwords are talked about."

To further show its commitment to regenerative agriculture, Hopdoddy is also one of the sponsors of Common Ground, a documentary about the pioneers of the regenerative movement, premiering October 4 in Austin. The "uplifting" film, according to a release, features well-known actors Laura Dern, Rosario Dawson, Jason Momoa, Woody Harrelson, Ian Somerhalder, and Donald Glover, emphasizing that this motley crew does share one thing in common: a strong belief in regenerative agriculture.

For more information about the new regenerative burgers, visit hopdoddy.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”